Ribomic Inc.

Tokyo Stock Exchange 4591.T

Ribomic Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 182.68 K

Ribomic Inc. Net Cash Used Provided By Financing Activities is USD 182.68 K for the year ending March 31, 2024, a -98.18% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Ribomic Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 10.04 M, a 244.52% change year over year.
  • Ribomic Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD 2.91 M, a -93.53% change year over year.
  • Ribomic Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 45.05 M, a 803.77% change year over year.
  • Ribomic Inc. Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD 4.98 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Tokyo Stock Exchange: 4591.T

Ribomic Inc.

CEO Mr. Yoshikazu Nakamura Ph.D.
IPO Date Sept. 25, 2014
Location Japan
Headquarters Shirokanedai Usui Building
Employees 24
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

StockViz Staff

February 8, 2025

Any question? Send us an email